ATE540037T1 - Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten - Google Patents

Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten

Info

Publication number
ATE540037T1
ATE540037T1 AT08758202T AT08758202T ATE540037T1 AT E540037 T1 ATE540037 T1 AT E540037T1 AT 08758202 T AT08758202 T AT 08758202T AT 08758202 T AT08758202 T AT 08758202T AT E540037 T1 ATE540037 T1 AT E540037T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
cycloalkyl
aryl
optionally substituted
Prior art date
Application number
AT08758202T
Other languages
English (en)
Inventor
Jakob Felding
Morten Syrensen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of ATE540037T1 publication Critical patent/ATE540037T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08758202T 2007-04-16 2008-04-16 Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten ATE540037T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91202007P 2007-04-16 2007-04-16
PCT/DK2008/000135 WO2008125111A1 (en) 2007-04-16 2008-04-16 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
ATE540037T1 true ATE540037T1 (de) 2012-01-15

Family

ID=39539479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08758202T ATE540037T1 (de) 2007-04-16 2008-04-16 Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten

Country Status (7)

Country Link
US (1) US8829190B2 (de)
EP (1) EP2146989B1 (de)
JP (1) JP2010523725A (de)
CN (1) CN101679428A (de)
AT (1) ATE540037T1 (de)
ES (1) ES2380395T3 (de)
WO (1) WO2008125111A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006428A (es) 2008-12-19 2011-07-28 Leo Pharma As Triazolopiridinas como inhibidores de fosfodiesterasa para tratamiento de enfermedades dermicas.
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010117926A1 (en) * 2009-04-07 2010-10-14 Schering Corporation Substituted triazolopyridines and analogs thereof
EP2438066A2 (de) 2009-06-05 2012-04-11 Cephalon, Inc. Zubereitung und verwendung von 1,2,4-triazol [1,5a]pyridinderivaten
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
JP6138150B2 (ja) 2011-12-21 2017-05-31 レオ ファーマ アクティーゼルスカブ ［１，２，４］トリアゾロピリジンおよびホスホジエステラーゼ阻害剤としてのその使用
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
EP3277689B1 (de) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclische verbindungen als lsd1-hemmer
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1163493C (zh) 1995-05-19 2004-08-25 协和发酵工业株式会社 含氧杂环化合物
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EP0943613A4 (de) 1996-11-19 2002-07-10 Kyowa Hakko Kogyo Kk Sauerstoff enthaltende heterocyclische verbindungen
DE602004001676T2 (de) * 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
JP2008515874A (ja) * 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬

Also Published As

Publication number Publication date
EP2146989A1 (de) 2010-01-27
JP2010523725A (ja) 2010-07-15
US8829190B2 (en) 2014-09-09
US20100113442A1 (en) 2010-05-06
ES2380395T3 (es) 2012-05-11
EP2146989B1 (de) 2012-01-04
WO2008125111A1 (en) 2008-10-23
CN101679428A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
HK1138262A1 (en) Novel phosphodiesterase inhibitors
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MY177250A (en) Novel nicotinamide derivative or salt thereof
AR083842A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
DK1723138T3 (da) Substituerede benzimidazoler og deres anvendelse til at inducere apoptose
MA32460B1 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.